CSL Behring Clinical Trials
Sponsors / CSL Behring
CSL Behring is listed as the lead sponsor on 186 clinical trials registered with ClinicalTrials.gov. Across the portfolio, 18 are in recruitment, 5 are active non-recruiting, and 135 have reached completion. 21 trials have been terminated or withdrawn. The most common reasons cited for termination include safety concerns, slow or insufficient recruitment. Across the portfolio, planned enrollment totals 92,400 participants. Data on this page mirrors the ClinicalTrials.gov registry as of the most recent refresh.
186
Total Trials
18
Recruiting
5
Other Active
135
Completed
21
Terminated / Withdrawn
92,400
Total Enrollment
Termination reasons: Safety29% · Other24% · Recruitment19% · Efficacy14% · Funding10% · Business5%
Recent Terminations
- Post-COVID Postural Orthostatic Tachycardia Syndrome"Sponsor decision, not for safety reasons."
- Dermatomyositis"Primary endpoint not attained"
- Traumatic Injury"Study was terminated early because mortality was lower than expected and a significant increase in sample size would have been required to meet statistical goals of the study. No safety reasons were involved in the decision to terminate the"
- NCT05614128 Stopped Sep 2024CIDP"Difficulty with Recruitment, Lack of Funding"
- Antibody-mediated Rejection"Early stop for lack of efficacy/futility (at Interim analysis)"
- Immune Complex-mediated Autoimmune Diseases"Lack of clinical viability"
- Coronavirus Disease 2019 (COVID-19)"For business reasons, not a safety issue"
- Anemia, Sickle Cell"Unanticipated delays, not for safety reasons"
- COVID-19"Study terminated due to poor enrollment. Data was not analyzed or disclosed due to subject confidentiality being an issue (n=1)."
- NCT03779828 Stopped Jun 2019Chronic Inflammatory Demyelinating Polyneuropathy"Due to logistical concerns"
Active Trials (5 total)
- NCT05485961
- NCT06699849
- NCT06738485
- NCT07076446
- NCT07080905
- NCT07094087
- NCT06617897
- Hereditary Angioedema PHASE4NCT06806657
- NCT06008938
- Sickle Cell Disease PHASE2NCT07224360
- NCT07332091
- Hemophilia B PHASE3NCT06399289
- Eosinophilic Esophagitis PHASE2NCT05485155
- Hemophilia B PHASE3NCT06003387
- NCT07001280
- NCT07048262
- NCT03684018
- NCT05360706
- NCT06878105
- NCT05086575